News

Filter

Current filters:

Janssen-CilagPricing

1 to 9 of 10 results

NZ’s PHARMAC awards sole supply to Eprex to Janssen-Cilag

NZ’s PHARMAC awards sole supply to Eprex to Janssen-Cilag

05-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has awarded sole subsidised supply status in…

BiotechnologyErythropoiesis-stimulating agentserythropoietinJanssen-CilagJohnson & JohnsonNew ZealandOncologyPricing

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

17-06-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGermanyInvokanaJanssen-CilagJohnson & JohnsonPharmaceuticalPricingRegulation

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

NICE seeks more data on J&J’s Velcade for multiple myeloma

NICE seeks more data on J&J’s Velcade for multiple myeloma

12-11-2013

In draft guidance published today, the UK’s drugs watchdog the National Institute of Health and Care…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalPricingRegulationVelcade

Positive NICE news for Gilenya for MS and Incivo for hep C

16-03-2012

There was good news from the UK drugs watchdog the Institute for Health and Clinical Excellence (NICE)…

Anti-viralsEuropeGilenyaIncivoJanssen-CilagJohnson & JohnsonNeurologicalNovartisPharmaceuticalPricingRegulation

1 to 9 of 10 results

Back to top